N30 Pharmaceuticals Announces Presentations at the 2013 North American Cystic Fibrosis Conference
BOULDER, Colo., Oct. 15, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. today announced presentations regarding its novel portfolio of compounds for the potential treatment of cystic fibrosis at the 2013 North American Cystic Fibrosis Conference, which will be held October 17-19, 2013 in Salt Lake City, Utah. The presentations include preclinical data on its first-in-class inhibitors of S-nitrosoglutathione reductase (GSNORi) and its novel correctors of CFTR, the dysfunctional protein in cystic fibrosis. N30 Pharmaceuticals, Inc. is conducting a clinical trial of its lead compound, N6022 (an injectable formulation) in cystic fibrosis patients homozygous for the F508del mutation. In parallel, the company is rapidly advancing an oral dosage form, N91115, through preclinical testing and plans to begin clinical trials of N91115 in the first half of 2014.
The following is a summary of the presentations that will be given at NACFC:
| Oral Presentations |
|
| Title: |
A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity |
| Presenter: |
Sherif E. Gabriel, Ph.D., VP Research and Discovery |
| Date: |
Thursday October 17 at 11:25 am |
| Session: |
Workshop Session 1: The CFTR 2013 Workshop highlights novel insights into CFTR biology 10:00-11:45 am |
| Title: |
Biomarkers from Bench to Bedside: Pharmaceutical Industry Perspective |
| Presenter: |
Janice M. Troha, EVP Product Development and Regulatory Affairs |
| Date: |
Thursday October 17 at 2:35 pm |
| Session: |
Symposium Session I: Assessing New CF Therapies: The Path to Biomarker Development 2:00-3:50 pm |
| Poster Presentations |
|
| Title: |
A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity |
| Presenter: |
Joan Blonder, Ph.D., Director Pharmacology |
| Date: |
Thursday October 17, 11:50am-1:50pm, and Friday October 18, 7:30am-8:45am, Hall C-D |
| Session: |
Posters, Number 6 (selected for oral presentation, above) |
| Title: |
Intestinal Current Measurement to Assess Modulation of F508del CFTR Function by GSNOR Inhibitor Treatment (In Vivo) |
| Presenter: |
Joan Blonder, Ph.D., Director Pharmacology |
| Date: |
Thursday October 17, 11:50am-1:50pm, and Friday October 18, 4-6pm, Hall C-D |
| Session: |
Posters, Number 7 |
| Title: |
Next Generation F508del CFTR correctors using a YFP based high throughput screening assay |
| Presenter: |
Xicheng Sun, Ph.D., Executive Director Chemistry |
| Date: |
Thursday October 17, 11:50am-1:50pm, and Friday October 18, 4-6pm, Hall C-D |
| Session: |
Posters, Number 29 |
About N30 Pharmaceuticals
N30 Pharmaceuticals, Inc. (N30 Pharma) is a privately held, clinical stage, biopharmaceutical company headquartered in Boulder, Colorado. It is the first company to discover and develop small molecules targeting GSNOR. N30 Pharma is dedicated to making a difference in the lives of patients with cystic fibrosis and their families.
| N30 Contacts |
|
| Email: [email protected] |
|
| Charles Scoggin, M.D. |
Wren Schauer |
| President and CEO |
Sr. Dir., IP, Tech. and Contracts |
| (720) 945 7721 |
(720) 945 7722 |
SOURCE N30 Pharmaceuticals, Inc.
Share this article